Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including ...
Ipsen Pharma: Ipsen delivers solid results in 2024, driven by strong performance across all therapeutic areas, and provides guidance for 2025
FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare Diseases portfolio, 9.2% ...